Epidemiology and outcome of bacteraemia in neutropenic patients in a single institution from 1991-2012

Epidemiology and Infection

Volumn 143, Issue 4, 2015, Pages 734-740

  Ortega, M ^a   Marco, F ^b   Soriano, A ^a   Almela, M ^b   Martinez J A ^a   Rovira, M ^a   Esteve, J ^a   Mensa, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Bacteraemia; empirical treatment; neutropenia; outcome

Indexed keywords

AMIKACIN; CEFOTAXIME; CORTICOSTEROID; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG USE; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; RISK FACTOR; SHOCK; COMPLICATION; CROSS INFECTION; ESCHERICHIA COLI INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84927964498     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814001654     Document Type: Article

References (22)

1. Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Annals of Oncology 2012; 23: 1889- 1893.
2. Hughes WT, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002; 34: 730-751.
3. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. Journal of Antimicrobial Chemotherapy 1998; 41 (Suppl. D): 13-24.
4. Pizzo PA. Empiric therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th edn. Philadelphia: Churchill Livingstone, 2000, pp. 3102-3111.
5. Klastersky J, Meunier-Carpentier F, Prevost JM. Significance of antimicrobial synergism for the outcome of gram-negative sepsis. American Journal of Medical Science 1977; 273: 157-161.
6. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. Reviews of Infectious Diseases 1982; 4: 294-298.
7. Hughes WT, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases 1997; 25: 551-573.
8. Wade JC. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy vs monotherapy. Journal of Infectious Diseases 1989; 11 (Suppl. 7): S1572-1581.
9. Del Favero A, Bucaneve G, Menichetti F. Empiric monotherapy in neutropenia: a realistic goal? Scandinavian Journal of Infectious Diseases 1995; 96 (Suppl.): 34-37.
10. Ramphal R. Monotherapy versus combination therapy for febrile neutropenia. International Journal of Hematology 1998; 68 (Suppl. 1): S21-25.
11. Murray PR, Baron EJ, Jorgensen JH (eds). Manual of Clinical Microbiology, 9th edn. Washington, DC: ASM Press, 2007.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Sixteenth Informational Supplement M100-S16. CLSI, Wayne, PA, USA, 2006.
13. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American Journal of Infection Control 2008; 36: 309-332.
14. Annane D, Bellisant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
15. Blot F, Nitenberg G, Brun-Buisson C. New tools in diagnosing catheter-related infections. Supportive Care in Cancer 2000; 8: 287-292.
16. Raad I, et al. Differential time to positivity: a useful method for diagnosing catheter-related infections. Annals of Internal Medicine 2004; 140: 18-25.
17. McCabe WR, Jackson GG. Gram-negative bacteraemia. II. Clinical, laboratory and therapeutic observations. Archives of Internal Medicine 1962; 110: 847-855.
18. Montaisser E, et al. Recent changes in bacteraemia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. European Journal of Clinical Microbiology Infectious Diseases 2013; 32: 841-850.
19. Averbuch D, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826-1835.
20. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infectious Diseases 2002; 2: 231-242.
21. Martinez JA, et al. Influence of empiric therapy with a β-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrobial Agents Chemotherapy 2010; 54: 3590-3596.
22. Romano S, et al. Population pharmacokinetics of amikacin in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy 1999; 44: 235-242.